Two groundbreaking cell-based gene therapies, exagamglogene autotemcel and lovotibeglogene autotemcel, were recently approved by the FDA for the treatment of sickle cell disease.
Olatunji Gbadebo, PharmD
Advertisement
Articles by Olatunji Gbadebo, PharmD
From finding mentors to maintaining a balanced lifestyle, these insights will empower students to navigate the ever-evolving world of pharmacy.
New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.
Advertisement
Latest Updated Articles
Advances in Sickle Cell Disease: New Gene Therapies and Management StrategiesPublished: September 16th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
3
G-CSF is a Potential Alternative in Treatment of Hot Flashes in Postmenopausal Women
4
CHEST 2025: Advancing Respiratory Virus Vaccines and Improving Uptake Among High-Risk Populations
5
